Table 1 Summary of preclinical studies on bromhexine
From: A reappraisal of the mucoactive activity and clinical efficacy of bromhexine
| Author | Cell type | BHC dosage | Outcomes |
|---|---|---|---|
| Merker 1966 [8] | Rats, bronchial secretory cells | 4-20 mg/kg/24 h parenteral | Quantitative and qualitative effect on mucus production |
| Janatuinen 1969 [10] | Guinea pigs, bronchial goblet cells | 5-10 mg/kg/24 h parenteral | Reduction in goblet cells, increased secretory material in airways |
| Gil 1971 [11] | Rats, type II alveolar cells | 200 mg/kg/24 h enteral | Increased secretion of phospholipids in alveolar space |
| Harada 1977 [12] | Dogs, tracheal mucosa | 4 mg intravenous | Increase in the output of secretion; goblet cells and submucosal mucus glands emptying |
| Von Wichert 1977 [14] | Rabbits, lung and liver tissues | 10 mg/kg intravenous | Rapid stimulation of phospholipid synthesis |
| Martin 1993 [27] | Pigs, rheological characteristics of tracheal mucus | 0,5 mg/kg | Increased concentration of oxytetracycline within the secreted mucus and reversed mucospastic activity of oxytetracycline in vivo |